Umeclidinium as (bromide), Vilanterol as (trifenatate)
Indications
Umeclidinium as (bromide), Vilanterol as (trifenatate) is used for:
UMECLIDINIUM
Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
VILANTEROL
Vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename breo ellipta and in combination with umeclidinium bromide as anoro ellipta. Approved by the fda in 2013, use of breo ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease
Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
VILANTEROL
Vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename breo ellipta and in combination with umeclidinium bromide as anoro ellipta. Approved by the fda in 2013, use of breo ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Umeclidinium as (bromide), Vilanterol as (trifenatate) :
Mechanism of Action
UMECLIDINIUM
Umeclidinium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors m1 to m5. In the airways, it exhibits pharmacological effects through the inhibition of m3 receptor at the smooth muscle leading to bronchodilation
VILANTEROL
Vilanterol is a selective long-acting beta2-adrenergic agonist. Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (atp) to cyclic-3',5'-adenosine monophosphate (camp). Increases in cyclic amp are associated with relaxation of bronchial smooth muscle and inhibition of release of hypersensitivity mediators from mast cells in the lungs
Umeclidinium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors m1 to m5. In the airways, it exhibits pharmacological effects through the inhibition of m3 receptor at the smooth muscle leading to bronchodilation
VILANTEROL
Vilanterol is a selective long-acting beta2-adrenergic agonist. Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (atp) to cyclic-3',5'-adenosine monophosphate (camp). Increases in cyclic amp are associated with relaxation of bronchial smooth muscle and inhibition of release of hypersensitivity mediators from mast cells in the lungs